Acumen Pharmaceuticals, Inc. (ABOS)
3.18
+0.09
(+2.91%)
USD |
NASDAQ |
Sep 04, 16:00
3.17
-0.01
(-0.31%)
After-Hours: 20:00
Acumen Pharmaceuticals Debt to Equity Ratio : 0.5526 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.5526 |
| March 31, 2026 | 0.3562 |
| December 31, 2025 | 0.4446 |
| September 30, 2025 | 0.331 |
| June 30, 2025 | 0.2571 |
| March 31, 2025 | 0.1915 |
| December 31, 2024 | 0.1634 |
| September 30, 2024 | 0.1381 |
| June 30, 2024 | 0.1218 |
| March 31, 2024 | 0.1167 |
| December 31, 2023 | 0.1163 |
| September 30, 2023 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0002 |
| March 31, 2023 | 0.0004 |
| December 31, 2022 | 0.0006 |
| September 30, 2022 | 0.0007 |
| June 30, 2022 | 0.0008 |
| March 31, 2022 | 0.0009 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Biogen, Inc. | 0.4433 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 116.01M |
| Total Liabilities (Quarterly) | 58.74M |
| Shareholders Equity (Quarterly) | 57.26M |
| Current Ratio | 2.466 |
| Net Debt Paydown Yield | -0.19% |